4,767,552 Shares in MiMedx Group, Inc $MDXG Purchased by Nantahala Capital Management LLC

Nantahala Capital Management LLC acquired a new position in MiMedx Group, Inc (NASDAQ:MDXG) during the second quarter, HoldingsChannel reports. The institutional investor acquired 4,767,552 shares of the company’s stock, valued at approximately $18,355,075.

Other institutional investors and hedge funds have also made changes to their positions in the company. SkyView Investment Advisors LLC lifted its holdings in shares of MiMedx Group by 3.6% during the second quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock valued at $523,000 after purchasing an additional 3,032 shares during the last quarter. Rafferty Asset Management LLC grew its stake in shares of MiMedx Group by 4.6% in the 4th quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock worth $469,000 after buying an additional 3,064 shares during the last quarter. Aviva PLC grew its stake in shares of MiMedx Group by 4.7% in the 4th quarter. Aviva PLC now owns 71,234 shares of the company’s stock worth $482,000 after buying an additional 3,211 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in MiMedx Group by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock valued at $559,000 after buying an additional 4,049 shares in the last quarter. Finally, AQR Capital Management LLC increased its position in MiMedx Group by 42.6% during the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock valued at $109,000 after buying an additional 4,296 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on MDXG shares. Seaport Research Partners cut MiMedx Group to a “neutral” rating in a research note on Monday, August 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $8.00 target price on shares of MiMedx Group in a research note on Monday, August 17th. Raymond James Financial set a $8.00 price target on MiMedx Group in a report on Monday, August 17th. Craig Hallum lifted their price target on MiMedx Group from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Wall Street Zen upgraded shares of MiMedx Group from a “sell” rating to a “hold” rating in a research note on Saturday. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.57.

MiMedx Group Trading Down 0.2%

NASDAQ:MDXG opened at $4.50 on Friday. The stock has a market cap of $655.92 million, a price-to-earnings ratio of 112.53 and a beta of 1.45. The company has a quick ratio of 4.79, a current ratio of 5.33 and a debt-to-equity ratio of 0.07. The company’s 50 day moving average price is $4.18 and its 200-day moving average price is $4.09. MiMedx Group, Inc has a 52 week low of $3.03 and a 52 week high of $7.97.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, July 29th. The company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%.The business had revenue of $64.36 million during the quarter, compared to analyst estimates of $63.46 million. On average, equities research analysts forecast that MiMedx Group, Inc will post -0.1 earnings per share for the current fiscal year.

MiMedx Group Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.